Eulav Asset Management Vertex Pharmaceuticals Inc Transaction History
Eulav Asset Management
- $4.06 Billion
- Q1 2025
A detailed history of Eulav Asset Management transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Eulav Asset Management holds 28,500 shares of VRTX stock, worth $10.4 Million. This represents 0.34% of its overall portfolio holdings.
Number of Shares
28,500
Previous 28,500
-0.0%
Holding current value
$10.4 Million
Previous $11.5 Million
20.4%
% of portfolio
0.34%
Previous 0.28%
Shares
30 transactions
Others Institutions Holding VRTX
# of Institutions
1,816Shares Held
232MCall Options Held
1.49MPut Options Held
1.07M-
Capital World Investors Los Angeles, CA28.5MShares$10.5 Billion2.34% of portfolio
-
Vanguard Group Inc Valley Forge, PA23.5MShares$8.61 Billion0.21% of portfolio
-
Black Rock Inc. New York, NY21.3MShares$7.81 Billion0.23% of portfolio
-
Capital Research Global Investors Los Angeles, CA14.5MShares$5.33 Billion1.6% of portfolio
-
State Street Corp Boston, MA11.8MShares$4.32 Billion0.24% of portfolio
About VERTEX PHARMACEUTICALS INC
- Ticker VRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 256,691,008
- Market Cap $94.1B
- Description
- Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...